Mobilisation of HLA-F on the surface of bronchial epithelial cells and platelets in asthmatic patients.
HLA-F
asthma
bronchial epithelial cells
cell activation
mobilisation
platelets
Journal
HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
26
07
2022
received:
29
03
2022
accepted:
16
08
2022
pubmed:
22
8
2022
medline:
18
10
2022
entrez:
21
8
2022
Statut:
ppublish
Résumé
Uncontrolled inflammation of the airways in chronic obstructive lung diseases leads to exacerbation, accelerated lung dysfunction and respiratory insufficiency. Among these diseases, asthma affects 358 million people worldwide. Human bronchial epithelium cells (HBEC) express both anti-inflammatory and activating molecules, and their deregulated expression contribute to immune cell recruitment and activation, especially platelets (PLT) particularly involved in lung tissue inflammation in asthma context. Previous results supported that HLA-G dysregulation in lung tissue is associated with immune cell activation. We investigated here HLA-F expression, reported to be mobilised on immune cell surface upon activation and displaying its highest affinity for the KIR3DS1-activating NK receptor. We explored HLA-F transcriptional expression in HBEC; HLA-F total expression in PBMC and HBEC collected from healthy individuals at rest and upon chemical activation and HLA-F membrane expression in PBMC, HBEC and PLT collected from healthy individuals at rest and upon chemical activation. We compared HLA-F transcriptional expression in HBEC from healthy individuals and asthmatic patients and its surface expression in HBEC and PLT from healthy individuals and asthmatic patients. Our results support that HLA-F is expressed by HBEC and PLT under healthy physiological conditions and is retained in cytoplasm, barely expressed on the surface, as previously reported in immune cells. In both cell types, HLA-F reaches the surface in the inflammatory asthma context whereas no effect is observed at the transcriptional level. Our study suggests that HLA-F surface expression is a ubiquitous post-transcriptional process in activated cells. It may be of therapeutic interest in controlling lung inflammation.
Identifiants
pubmed: 35988034
doi: 10.1111/tan.14782
pmc: PMC9804204
doi:
Substances chimiques
Anti-Inflammatory Agents
0
HLA-F antigens
0
HLA-G Antigens
0
Histocompatibility Antigens Class I
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
491-499Informations de copyright
© 2022 The Authors. HLA: Immune Response Genetics published by John Wiley & Sons Ltd.
Références
J Thorac Dis. 2021 Nov;13(11):6528-6535
pubmed: 34992832
Am Rev Respir Dis. 1992 Mar;145(3):571-6
pubmed: 1532119
Hum Immunol. 2000 Nov;61(11):1059-65
pubmed: 11137208
Gastroenterology. 2018 Nov;155(5):1366-1371.e3
pubmed: 30031767
Crit Rev Immunol. 2013;33(3):203-18
pubmed: 23756244
J Immunol. 2010 Jun 1;184(11):6199-208
pubmed: 20483783
Am J Transplant. 2015 Feb;15(2):461-71
pubmed: 25488753
J Immunol. 2011 Jul 1;187(1):11-9
pubmed: 21690332
Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11520-5
pubmed: 9326642
J Immunol. 2003 Aug 1;171(3):1376-84
pubmed: 12874228
Immunity. 2017 Jun 20;46(6):1018-1029.e7
pubmed: 28636952
Cytometry A. 2005 May;65(1):84-7
pubmed: 15779060
Am J Respir Crit Care Med. 2008 Mar 15;177(6):604-12
pubmed: 18096710
Int J Biol Sci. 2021 Mar 25;17(5):1263-1276
pubmed: 33867844
Metabolites. 2021 Aug 24;11(9):
pubmed: 34564383
Oncoimmunology. 2016 Sep 9;5(10):e1226720
pubmed: 27853650
Hum Immunol. 1997 Jan;52(1):33-40
pubmed: 9021407
BMC Med Genomics. 2018 Mar 27;11(1):36
pubmed: 29587858
Front Med (Lausanne). 2017 Aug 08;4:129
pubmed: 28848732
Front Immunol. 2018 Feb 23;9:278
pubmed: 29527207
Int J Immunogenet. 2019 Oct;46(5):307-320
pubmed: 31183978
Vox Sang. 2020 Jul;115(5):349-357
pubmed: 32293034
Front Immunol. 2017 Jan 23;8:6
pubmed: 28303134
Circ Res. 2018 Jan 19;122(2):337-351
pubmed: 29348254
Respir Res. 2011 Jun 23;12:86
pubmed: 21699702
Oncoimmunology. 2013 Nov 1;2(11):e26491
pubmed: 24482746
Am J Respir Cell Mol Biol. 2021 May;64(5):557-568
pubmed: 33556295
Am J Hum Genet. 2020 Aug 6;107(2):211-221
pubmed: 32649856
J Allergy Clin Immunol. 2017 Sep;140(3):857-860
pubmed: 28363527
3 Biotech. 2018 Jan;8(1):49
pubmed: 29354360
J Immunol. 2019 Nov 1;203(9):2357-2367
pubmed: 31636134
Am J Respir Cell Mol Biol. 2005 Sep;33(3):280-9
pubmed: 15961727
Hum Reprod. 2020 Mar 27;35(3):705-717
pubmed: 32020202
Int J Mol Sci. 2020 Oct 28;21(21):
pubmed: 33126487
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
Nat Med. 2012 May 04;18(5):684-92
pubmed: 22561832
J Immunol. 2003 Nov 15;171(10):5264-71
pubmed: 14607927
Immunology. 2021 Dec;164(4):701-721
pubmed: 34547115
Allergy. 2011 Feb;66(2):155-62
pubmed: 20722638
Nat Immunol. 2016 Sep;17(9):1067-74
pubmed: 27455421
HLA. 2022 Nov;100(5):491-499
pubmed: 35988034
Respir Res. 2013 Jan 18;14:4
pubmed: 23327606
J Allergy Clin Immunol. 2012 May;129(5):1259-1266.e1
pubmed: 22409990
J Proteome Res. 2021 Sep 3;20(9):4518-4528
pubmed: 34415762
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30987036
Am J Transplant. 2015 Sep;15(9):2413-20
pubmed: 25989360
Genome Res. 2017 May;27(5):813-823
pubmed: 28360230
PLoS One. 2016 Sep 20;11(9):e0163297
pubmed: 27649529
Eur J Immunol. 2010 Aug;40(8):2308-18
pubmed: 20865824
Am J Transplant. 2009 Jun;9(6):1427-38
pubmed: 19656137
Eur Respir Rev. 2021 Sep 15;30(161):
pubmed: 34526315
Eur Respir J. 2017 Mar 8;49(3):
pubmed: 28275176
J Immunol. 2000 Jan 1;164(1):319-28
pubmed: 10605026
Eur J Immunol. 2000 Dec;30(12):3552-61
pubmed: 11169396
Am J Respir Crit Care Med. 2012 Mar 1;185(5):498-507
pubmed: 22227382